Net Worth Advisory Group Invests $213,000 in Merus (NASDAQ:MRUS)

Net Worth Advisory Group acquired a new position in shares of Merus (NASDAQ:MRUS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,054 shares of the biotechnology company's stock, valued at approximately $213,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of MRUS. GAMMA Investing LLC grew its stake in Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 603 shares in the last quarter. State of Wyoming bought a new position in Merus during the 4th quarter worth approximately $48,000. Wells Fargo & Company MN lifted its holdings in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Merus in the 4th quarter worth approximately $60,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Merus in the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 96.14% of the company's stock.

Merus Price Performance

MRUS traded down $0.78 during trading on Friday, reaching $54.61. 711,649 shares of the stock traded hands, compared to its average volume of 749,264. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -13.83 and a beta of 1.04. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $62.98. The stock's 50-day simple moving average is $46.42 and its two-hundred day simple moving average is $44.30.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The company had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. Research analysts anticipate that Merus will post -3.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MRUS. Wells Fargo & Company cut their price target on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. William Blair restated an "outperform" rating on shares of Merus in a research report on Monday, April 28th. HC Wainwright restated a "buy" rating and issued a $85.00 target price on shares of Merus in a research report on Monday, March 3rd. Bank of America lowered their target price on Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, BMO Capital Markets set a $110.00 target price on Merus and gave the company an "outperform" rating in a research report on Friday, May 23rd. Thirteen investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $85.83.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.